Cardiovascular Digital Health Journal (Dec 2021)

Rationale and design of the SafeHeart study: Development and testing of a mHealth tool for the prediction of arrhythmic events and implantable cardioverter-defibrillator therapy

  • Diana M. Frodi, MD,
  • Maarten Z.H. Kolk, MD, MSc,
  • Joss Langford, BSc,
  • Tariq O. Andersen, PhD,
  • Reinoud E. Knops, MD, PhD,
  • Hanno L. Tan, MD, PhD,
  • Jesper H. Svendsen, MD, DMSc, FESC, FEHRA,
  • Fleur V.Y. Tjong, MD, PhD,
  • Soeren Z. Diederichsen, MD, PhD

Journal volume & issue
Vol. 2, no. 6
pp. S11 – S20

Abstract

Read online

Background: Patients with an implantable cardioverter-defibrillator (ICD) are at a high risk of malignant ventricular arrhythmias. The use of remote ICD monitoring, wearable devices, and patient-reported outcomes generate large volumes of potential valuable data. Artificial intelligence–based methods can be used to develop personalized prediction models and improve early-warning systems. Objective: The purpose of this study was to develop an integrated web-based personalized prediction engine for ICD therapy. Methods: This international, multicenter, prospective, observational study consists of 2 phases: (1) a development study and (2) a feasibility study. We plan to enroll 400 participants with an ICD (with or without cardiac resynchronization therapy) on remote monitoring: 300 participants in the development study and 100 in the feasibility study. During 12-month follow-up, electronic health record data, remote monitoring data, accelerometry-assessed physical behavior data, and patient-reported data are collected. By using machine- and deep-learning approaches, a prediction engine is developed to assess the risk probability of ICD therapy (shock and antitachycardia pacing). The feasibility of the prediction engine as a clinical tool, the SafeHeart Platform, is assessed during the feasibility study. Results: Development study recruitment commenced in 2021. The feasibility study starts in 2022. Conclusion: SafeHeart is the first study to prospectively collect a multimodal data set to construct a personalized prediction engine for ICD therapy. Moreover, SafeHeart explores the integration and added value of detailed objective accelerometer data in the prediction of clinical events. The translation of the SafeHeart Platform to clinical practice is examined during the feasibility study.

Keywords